Breaking News

Takeda's COVID-19 Vaccine Strategy in Japan Advances

February 24, 2021 • 6:53 am CST
(Precision Vaccinations News)

Takeda Pharmaceutical Company Limited announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. The results from the TAK-019 study are expected in the second half of 2021.

“Early in the pandemic, we made the decision to partner with other companies and leverage our substantial vaccine experience and capabilities to make COVID-19 vaccines available in Japan,” commented Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda, in a press release. Takeda previously announced its commitment to providing rapid and sustained access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna.

Takeda confirmed it will receive a manufacturing technology transfer from Novavax and would be responsible for the development and commercialization based on manufacturing capacity of over 250 million doses of TAK-019.

The company will also import and distribute 50 million doses of TAK-919 as part of a joint partnership with Moderna and the Government of Japan’s Ministry of Health Labour and Welfare. Earlier, Takeda announced the completed enrollment (200) in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan. Results from the TAK-919 study are expected in the first half of 2021.

Based in Osaka, Japan, Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

Our Trust Standards: Medical Advisory Committee

Share